[go: up one dir, main page]

EP3793530A1 - Solid dispersion containing ritonavir - Google Patents

Solid dispersion containing ritonavir

Info

Publication number
EP3793530A1
EP3793530A1 EP19725121.8A EP19725121A EP3793530A1 EP 3793530 A1 EP3793530 A1 EP 3793530A1 EP 19725121 A EP19725121 A EP 19725121A EP 3793530 A1 EP3793530 A1 EP 3793530A1
Authority
EP
European Patent Office
Prior art keywords
solid dispersion
ritonavir
pharmaceutical composition
cationic polymer
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19725121.8A
Other languages
German (de)
French (fr)
Inventor
Panagiotis PANAGOPOULOS
Konstantinos-Emmanouil PANITSAS
Konstantinos KOMPOROZOS
Aggelos Likoudis
Matthaios Syrigos
Maria Hatzouli
Charalambos PATTIHIS
Antje NORDMANN
Michalis NEOPTOMEMOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedica Ltd
Pharmaceutical Oriented Services Ltd
Original Assignee
Remedica Ltd
Pharmaceutical Oriented Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedica Ltd, Pharmaceutical Oriented Services Ltd filed Critical Remedica Ltd
Publication of EP3793530A1 publication Critical patent/EP3793530A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a solid dispersion containing ritonavir and to its use in the preparation of a solid pharmaceutical composition.
  • Ritonavir has a low solubility in aqueous media as well as low membrane permeability, so that this drug is classified as a class IV compound according to the Biopharmaceutics Classification System (BCS).
  • Class IV drugs are generally difficult to be formulated as a unit dosage form for oral administration, because adequate oral bioavailability cannot easily be achieved.
  • lipid based delivery systems e.g. lipid based delivery systems, polymer based nano-carriers, crystal engineering (nano-crystals and co-crystals), liquisolid technology and self-emulsifying solid dispersions
  • Self-emulsifying solid dispersions consist of a dispersion of the drug in an inert excipient matrix, where the drug may exist in finely divided crystalline or amorphous states or in a molecularly dispersed form (solid solution).
  • Typical self-emulsifying polymers which may be employed as pharmaceutical excipients constituting the matrix of the solid dispersion, are lauroyl polyoxylglycerides (e.g. PEG-32 lauroyl polyoxylglyceride (Gelucire ® 44/14)), tocopheryl polyethylene glycol 1000 succinate (TPGS) or polyoxyethylene/polyoxy- propylene copolymer (poloxamer (Pluronics ® )).
  • lauroyl polyoxylglycerides e.g. PEG-32 lauroyl polyoxylglyceride (Gelucire ® 44/14)
  • TPGS tocopheryl polyethylene glycol 1000 succinate
  • polyoxyethylene/polyoxy- propylene copolymer polyoxyethylene/polyoxy- propylene copolymer
  • Ritonavir is marketed under the tradename Norvir ® in the form of a soft capsule or tablet.
  • a fixed combination of ritonavir and lopinavir is marketed under the tradename Kaletra ® in the form of a soft capsule or tablet.
  • the mono and the combination product are indicated in combination with other antiretroviral agents for the treatment of HIV- 1 infection.
  • ritonavir Two polymorphs of ritonavir (forms I and II) are known. The preparation of these forms as well as the preparation of amorphous ritonavir is described in WO 00/04016.
  • Form II is the thermodynamically stable form and is much less soluble than form I.
  • the Norvir ® and Kaletra ® soft capsules were developed in order to suppress the formation of the form II.
  • the Norvir ® soft capsule contains a solution of ritonavir in ethanol, oleic acid, water and polyoxyl 35 castor oil. In the Kaletra ® soft capsule, propylene glycol is used instead of ethanol.
  • the crystallization of form II ritonavir is suppressed if the capsules are stored at 5 °C.
  • the Norvir ® and Kaletra ® film-coated tablets show, compared to the soft capsule formulations, both improved storage stability (the tablets may be stored at room temperature without formation of form II ritonavir) and enhanced oral bioavaila bility.
  • the tablet cores contain copovidone, sorbitan monolaurate, colloidal anhydrous silica and sodium stearyl fumarate, whereby the Norvir ® tablet additionally contains anhydrous calcium hydrogen phosphate.
  • the tablets are prepared by hot-melt extrusion, which affords a solid solution of the active substances in the matrix.
  • the main excipient is copovidone, a copolymer of vinylpyrrolidone and vinyl acetate (60 %/40 %).
  • WO 01/34118 describes a solid dispersion containing ritonavir.
  • the matrix is formed by a water-soluble carrier, e.g. by polyethylene glycol (PEG), poloxamer, polyoxy ethylene stearate or poly-e-caprolactone.
  • PEG polyethylene glycol
  • the solid dispersion is prepared by dissolving ritonavir in an organic solvent, preferably ethanol, dissolving the drug in the water-soluble polymer by adding the polymer to the solution and removing the organic solvent by evaporation.
  • the preferred water-soluble polymer is PEG.
  • the dissolution rate of ritonavir depends on the drug load: the higher the drug load, the lower the drug release from particles containing ritonavir dissolved in PEG.
  • the in vitro dissolution profile correlates with the oral bioavailability; the best oral bioavailability was found with the lowest drug load.
  • WO 2005/039551 and WO 2006/091529 relate to the Kaletra ® tablet. They describe a solid solution containing ritonavir and lopinavir within a water-soluble polymer, whereby the solid solution is prepared by hot-melt extrusion.
  • the preferred water- soluble polymer is copovidone.
  • the blend to be subjected to melt-extrusion should contain a surfactant having a hydrophilic-lipophilic balance (HLB) value of 4-10.
  • HLB hydrophilic-lipophilic balance
  • the preferred surfactants are sorbitan monolaurate and sorbitan monopalmitate.
  • WO 2009/081174 discloses a bilayer tablet containing darunavir in one layer and ritonavir in the other layer. It is stated in the application that the drugs may be dissolved/dispersed by hot-melt extrusion within a matrix containing a water-soluble and/or water-insoluble polymer, whereby the drug : polymer ratio should range from 1 : 1 to 1 : 6.
  • the preferred water-soluble polymer is copovidone, while examples of water-insoluble polymers include acrylic copolymers (e.g. Eudragit ® E), polyvinyl acetate, ethyl cellulose and cellulose acetate.
  • the darunavir-layer is preferably prepared by wet-granulation in which a mixture of darunavir, microcrystalline cellulose and crospovidone is treated with a polyvinylpyrrolidone-containing aqueous solution.
  • the ritonavir-layer is preferably prepared by holt-melt extrusion of a mixture containing the drug, copovidone and sorbitan monolaurate or polyoxyethylene castor oil (Cremophor ® ).
  • the ritonavir-containing tablets described in the prior art solve the oral bioavailability problem of the BCS class IV drug ritonavir by formulating the drug as a solid dispersion, i.e. by dissolving the drug in a self-emulsifying water-soluble polymer matrix.
  • a self-emulsifying polymers as Gelucire ® 44/14, TPGS or poloxamers
  • a combination of a water-soluble polymer and a surfactant is employed. It was an objective of the present invention to provide an alternative ritonavir-containing pharmaceutical composition, in which the formation of crystalline ritonavir, in particular of form II ritonavir is suppressed and which shows adequate oral bioavailability. This objective is attained by the subject matter as defined in the claims.
  • the present invention relates to a solid dispersion comprising ritonavir, a cationic polymer containing an amino group, and optionally a pharmaceutical excipient. It is preferred that the solid dispersion contains ritonavir in a molecularly dispersed form (solid solution). In another embodiment of the present invention, the solid dispersion may contain particles of ritonavir in the amorphous state.
  • the solid dispersion of the present invention serves the purpose of enhancing oral bioavailability of ritonavir.
  • the drug dissolves along with the cationic polymer containing an amino group to create a supersaturated solution.
  • the drug may crystallize, so that the dissolution advantage of the solid dispersion is lost.
  • the crystallization of ritonavir was suppressed by suspending the drug in a matrix of a water-soluble polymer and a surfactant. According to the present invention, no surfactant is required if ritonavir is dispersed in a cationic polymer containing an amino group.
  • a cationic polymer containing an amino group suppresses the crystallization of ritonavir in the gastrointestinal fluid.
  • Cationic polymers with amino groups have water solubility at acidic pH but not at neutral pH or above pH 7. This is achieved by the presence of the amino group that is protonated under acidic conditions.
  • the cationic polymer used in the present invention is soluble in water at a pH of 6.5 or below, preferably at a pH of 6 or below. It is assumed that the water penetration into the solid dispersion is delayed until the solid dispersion reaches the stomach. In the stomach (pH 1-3.5) the solid dispersion dissolves due to the protonation of the cationic polymer.
  • the weight ratio of the cationic polymer to ritonavir is usually 6 : 1 to 1 : 2, preferably 3 : 1 to 2 : 3, more preferred 3 : 2 to 1 : 1.
  • the cationic polymer is selected from aminoalkyl methacrylate copolymer, polyvinylacetal diethylaminoacetate and chitosan.
  • aminoalkyl methacrylate copolymer butyl methacrylate/(2-dimethylaminoethyl)- methacrylate/methyl methacrylate copolymer (1 : 2 : 1), which is marketed under the tradename Eudragit ® E, may be used.
  • Chitosan is soluble in water at a pH of 6.5 and below; Eudragit ® E is soluble in water at a pH of 5 or below, while polyvinylacetal diethylaminoacetate is soluble in water at a pH of 5.8 and below.
  • the solid dispersion of the present invention may contain a pharmaceutical excipient selected from a filler, a disintegrant and a surfactant.
  • fillers examples include microcrystalline cellulose, calcium hydrogen phosphate (anhydrous or dihydrate), lactose (anhydrous or monohydrate), calcium carbonate, magnesium carbonate, silicified microcrystalline cellulose, powder cellulose and mannitol.
  • the filler is selected from microcrystalline cellulose, powder cellulose, silicified microcrystalline cellulose and calcium hydrogen phosphate, whereby microcrystalline cellulose is most preferably used.
  • disintegrants examples include sodium starch glycolate, croscarmellose sodium and crospovidone, whereby the most preferred disintegrant is crospovidone.
  • surfactants include polyoxyethylene stearate, sodium lauryl sulphate, sorbitan fatty acid esters (e.g. sorbitan monolaurate or sorbitan monopalmitate), polyoxyethylene sorbitan fatty acid esters (e.g. Polysorbate 80) and polyoxyethylene castor oil.
  • sorbitan fatty acid esters e.g. sorbitan monolaurate or sorbitan monopalmitate
  • polyoxyethylene sorbitan fatty acid esters e.g. Polysorbate 80
  • polyoxyethylene castor oil e.g. Polysorbate 80
  • the solid dispersion consists of ritonavir, the cationic polymer, a filler and a disintegrant.
  • the cationic polymer is an aminoalkyl methacrylate copolymer, e.g. butyl methacrylate/(2-di- methylaminoethyl)methacrylate/methyl methacrylate copolymer (1 : 2 : 1)
  • the filler is microcrystalline cellulose
  • the disintegrant is crospovidone.
  • the present invention also relates to a pharmaceutical composition for oral administration containing the solid dispersion of the present invention.
  • the pharmaceutical composition may contain, besides the pharmaceutical excipients optionally contained in the solid dispersion, a filler, disintegrant and surfactant, which may be identical to those contained in the solid dispersion.
  • the pharmaceutical composition may, additionally, contain a binder, a glidant and/or a lubricant.
  • binders examples include hydroxypropyl methylcellulose (HPMC), methylcellu- lose, hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (povidone), polyvinyl alcohol, a vinylpyrrolidone/vinyl acetate copolymer (e.g. copovidone) and pregelati nized starch.
  • glidants examples include silicon dioxide (silica) and magnesium silicate.
  • lubricants examples include magnesium stearate, calcium stearate, zinc stearate, talc, sodium stearyl fumarate and glyceryl dibehenate.
  • the pharmaceutical composition of the present invention may be a tablet (including multiparticulate drug delivery systems) or a capsule that contains the solid dispersion of the present invention as particles (powder, granules or pellets), optionally in admixture with pharmaceutical excipients, and/or as minitablets.
  • the pharmaceutical composition of the present invention is preferably a tablet optionally coated with a film-coating.
  • a film-coating Commercially available film-coating systems containing polyvinyl alcohol as coating polymer, which are marketed under the tradename Opadry ® , may be used.
  • the pharmaceutical composition may further contain a HIV protease inhibitor. If present, the HIV protease inhibitor is preferably not contained in the ritonavir- containing solid dispersion.
  • the HIV protease inhibitor may be selected from darunavir, lopinavir, atazanavir, tipranavir and saquinavir.
  • the pharmaceutical composition is an optionally film-coated multi-layer tablet containing ritonavir in a first layer and the HIV protease inhibitor in a second layer.
  • the multi-layer tablet may be an optionally film-coated bilayer tablet containing ritonavir in the first layer and darunavir in the second layer.
  • the pharmaceutical composition of the present invention is suitable, optionally in combination with other antiretroviral agents, for the treatment of HIV infection, e.g. HIV-l infection.
  • the solid dispersion of the present invention may be prepared by melt-extrusion, spray-drying or spray-granulation, whereby spray-granulation is the preferred method.
  • the solid dispersion of the present invention may be prepared by i) dissolving ritonavir and the cationic polymer containing an amino group in a granulation liquid, and
  • step (i) spraying the solution obtained in step (i) onto a pharmaceutical excipient to obtain the solid dispersion in form of granules.
  • the granulation liquid is an organic solvent, preferably an alcohol, such as ethanol.
  • the pharmaceutical excipient used in method step (ii) is selected from a filler and a disintegrant.
  • the pharmaceutical composition for oral administration according to the present invention may be prepared by iii) mixing the solid dispersion of the present invention, which is preferably obtained by steps (i) and (ii) mentioned above, and a pharmaceutical excipient, and
  • step (iii) subjecting the mixture obtained in step (iii) to compression.
  • the pharmaceutical composition contains a filler and disintegrant in the solid dispersion, i.e. as intragranular compo nents, and a disintegrant, lubricant and glidant as extragranular components.
  • the HIV protease inhibitor is preferably not contained in the ritonavir- containing solid dispersion. This can be achieved by iii) mixing the solid dispersion of the present invention, which is preferably obtained by steps (i) and (ii) mentioned above, a pharmaceutical excipient and the HIV protease inhibitor, and
  • step (iii) subjecting the mixture obtained in step (iii) to compression.
  • the HIV protease inhibitor is contained in the pharmaceutical composition as extragranular component.
  • the ritonavir-containing solid dispersion is contained in a first layer and the HIV protease inhibitor is contained in a second layer of an optionally film-coated multi-layer tablet.
  • the HIV protease inhibitor is darunavir.
  • the present invention also relates to a bilayer tablet containing ritonavir in a first layer and darunavir in a second layer.
  • the optionally film-coated bilayer tablet may be prepared by i) dissolving ritonavir and the cationic polymer containing an amino group in a granulation liquid,
  • step (i) spraying the solution obtained in step (i) onto a pharmaceutical excipient to obtain a solid dispersion in the form of granules
  • step (iii) mixing the solid dispersion obtained in step (ii) and a pharmaceutical excipient, v) subjecting a mixture containing darunavir and a pharmaceutical excipient to dry-granulation,
  • step (v) mixing the granules obtained in step (v) and a pharmaceutical excipient, vii) layering the mixture obtained in step (iii) onto the mixture obtained in step (vi),
  • step (viii) subjecting the two layers obtained in step (vii) to compression, and ix) optionally subjecting the bilayer tablet obtained in step (viii) to film-coating.
  • the pharmaceutical excipient used in step (ii) is a filler and a disintegrant
  • the pharmaceutical excipient used in steps (iii) and (vi) is a disintegrant, a glidant and a lubricant
  • the pharmaceutical excipient used in step (v) is a filler and a lubricant.
  • A-l Sift all dry mix materials through appropriate sieve
  • A-2 Mix the sifted materials for appropriate time
  • A-3 Lubricate the mix with magnesium stearate
  • A-4 Compact the lubricated blend using roller compactor
  • A-6 Blend sifted granules for appropriate time
  • A-7 To the final sifted and blended granules of appropriate particle size distribution add crospovidone and colloidal silicon dioxide and mix for appropriate time
  • A-8 Lubricate the mixed product of previous step with magnesium stearate
  • step B-4 Spray granulate with the solution of step B-2 to obtain a solid solution of ritonavir within a Eudragit ® matrix

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a solid dispersion containing ritonavir and a cationic polymer, and to the use of the solid dispersion for the preparation of a pharmaceutical composition for oral administration, which is preferably a tablet. The pharmaceutical composition is intended for the treatment of HIV and may additionally contain a HIV protease inhibitor selected from darunavir, lopinavir, atazanavir, tipranavir and saquinavir.

Description

Solid dispersion containing ritonavir
The present invention relates to a solid dispersion containing ritonavir and to its use in the preparation of a solid pharmaceutical composition.
Ritonavir has a low solubility in aqueous media as well as low membrane permeability, so that this drug is classified as a class IV compound according to the Biopharmaceutics Classification System (BCS). Class IV drugs are generally difficult to be formulated as a unit dosage form for oral administration, because adequate oral bioavailability cannot easily be achieved.
Various techniques have been employed in the state of the art in order to enhance the oral bioavailability of BCS class IV drugs, e.g. lipid based delivery systems, polymer based nano-carriers, crystal engineering (nano-crystals and co-crystals), liquisolid technology and self-emulsifying solid dispersions ( Journal of Controlled Release 2017, 248, 71-95). Self-emulsifying solid dispersions consist of a dispersion of the drug in an inert excipient matrix, where the drug may exist in finely divided crystalline or amorphous states or in a molecularly dispersed form (solid solution). Typical self-emulsifying polymers, which may be employed as pharmaceutical excipients constituting the matrix of the solid dispersion, are lauroyl polyoxylglycerides (e.g. PEG-32 lauroyl polyoxylglyceride (Gelucire® 44/14)), tocopheryl polyethylene glycol 1000 succinate (TPGS) or polyoxyethylene/polyoxy- propylene copolymer (poloxamer (Pluronics®)).
Ritonavir is marketed under the tradename Norvir® in the form of a soft capsule or tablet. In addition, a fixed combination of ritonavir and lopinavir is marketed under the tradename Kaletra® in the form of a soft capsule or tablet. The mono and the combination product are indicated in combination with other antiretroviral agents for the treatment of HIV- 1 infection.
Two polymorphs of ritonavir (forms I and II) are known. The preparation of these forms as well as the preparation of amorphous ritonavir is described in WO 00/04016. Form II is the thermodynamically stable form and is much less soluble than form I. Hence, there is a high risk that a unit dosage form containing ritonavir form I may exhibit a dramatic decrease of oral bioavailability if the form I transforms into form II during storage. The Norvir® and Kaletra® soft capsules were developed in order to suppress the formation of the form II. The Norvir® soft capsule contains a solution of ritonavir in ethanol, oleic acid, water and polyoxyl 35 castor oil. In the Kaletra® soft capsule, propylene glycol is used instead of ethanol. The crystallization of form II ritonavir is suppressed if the capsules are stored at 5 °C.
The Norvir® and Kaletra® film-coated tablets show, compared to the soft capsule formulations, both improved storage stability (the tablets may be stored at room temperature without formation of form II ritonavir) and enhanced oral bioavaila bility. The tablet cores contain copovidone, sorbitan monolaurate, colloidal anhydrous silica and sodium stearyl fumarate, whereby the Norvir® tablet additionally contains anhydrous calcium hydrogen phosphate. The tablets are prepared by hot-melt extrusion, which affords a solid solution of the active substances in the matrix. The main excipient is copovidone, a copolymer of vinylpyrrolidone and vinyl acetate (60 %/40 %).
WO 01/34118 describes a solid dispersion containing ritonavir. The matrix is formed by a water-soluble carrier, e.g. by polyethylene glycol (PEG), poloxamer, polyoxy ethylene stearate or poly-e-caprolactone. The solid dispersion is prepared by dissolving ritonavir in an organic solvent, preferably ethanol, dissolving the drug in the water-soluble polymer by adding the polymer to the solution and removing the organic solvent by evaporation. The preferred water-soluble polymer is PEG. The dissolution rate of ritonavir depends on the drug load: the higher the drug load, the lower the drug release from particles containing ritonavir dissolved in PEG. The in vitro dissolution profile correlates with the oral bioavailability; the best oral bioavailability was found with the lowest drug load.
WO 2005/039551 and WO 2006/091529 relate to the Kaletra® tablet. They describe a solid solution containing ritonavir and lopinavir within a water-soluble polymer, whereby the solid solution is prepared by hot-melt extrusion. The preferred water- soluble polymer is copovidone. In order to increase the oral bioavailability of the drugs, the blend to be subjected to melt-extrusion should contain a surfactant having a hydrophilic-lipophilic balance (HLB) value of 4-10. The preferred surfactants are sorbitan monolaurate and sorbitan monopalmitate.
WO 2009/081174 discloses a bilayer tablet containing darunavir in one layer and ritonavir in the other layer. It is stated in the application that the drugs may be dissolved/dispersed by hot-melt extrusion within a matrix containing a water-soluble and/or water-insoluble polymer, whereby the drug : polymer ratio should range from 1 : 1 to 1 : 6. The preferred water-soluble polymer is copovidone, while examples of water-insoluble polymers include acrylic copolymers (e.g. Eudragit® E), polyvinyl acetate, ethyl cellulose and cellulose acetate. The darunavir-layer is preferably prepared by wet-granulation in which a mixture of darunavir, microcrystalline cellulose and crospovidone is treated with a polyvinylpyrrolidone-containing aqueous solution. The ritonavir-layer is preferably prepared by holt-melt extrusion of a mixture containing the drug, copovidone and sorbitan monolaurate or polyoxyethylene castor oil (Cremophor®).
The ritonavir-containing tablets described in the prior art solve the oral bioavailability problem of the BCS class IV drug ritonavir by formulating the drug as a solid dispersion, i.e. by dissolving the drug in a self-emulsifying water-soluble polymer matrix. Instead of using self-emulsifying polymers, as Gelucire® 44/14, TPGS or poloxamers, a combination of a water-soluble polymer and a surfactant is employed. It was an objective of the present invention to provide an alternative ritonavir-containing pharmaceutical composition, in which the formation of crystalline ritonavir, in particular of form II ritonavir is suppressed and which shows adequate oral bioavailability. This objective is attained by the subject matter as defined in the claims.
The present invention relates to a solid dispersion comprising ritonavir, a cationic polymer containing an amino group, and optionally a pharmaceutical excipient. It is preferred that the solid dispersion contains ritonavir in a molecularly dispersed form (solid solution). In another embodiment of the present invention, the solid dispersion may contain particles of ritonavir in the amorphous state.
The solid dispersion of the present invention serves the purpose of enhancing oral bioavailability of ritonavir. After oral administration of the solid dispersion, the drug dissolves along with the cationic polymer containing an amino group to create a supersaturated solution. After dissolution of a solid dispersion in the gastrointestinal fluid, the drug may crystallize, so that the dissolution advantage of the solid dispersion is lost. In the prior art formulations, the crystallization of ritonavir was suppressed by suspending the drug in a matrix of a water-soluble polymer and a surfactant. According to the present invention, no surfactant is required if ritonavir is dispersed in a cationic polymer containing an amino group.
It was found that a cationic polymer containing an amino group suppresses the crystallization of ritonavir in the gastrointestinal fluid. Cationic polymers with amino groups have water solubility at acidic pH but not at neutral pH or above pH 7. This is achieved by the presence of the amino group that is protonated under acidic conditions. The cationic polymer used in the present invention is soluble in water at a pH of 6.5 or below, preferably at a pH of 6 or below. It is assumed that the water penetration into the solid dispersion is delayed until the solid dispersion reaches the stomach. In the stomach (pH 1-3.5) the solid dispersion dissolves due to the protonation of the cationic polymer.
The weight ratio of the cationic polymer to ritonavir is usually 6 : 1 to 1 : 2, preferably 3 : 1 to 2 : 3, more preferred 3 : 2 to 1 : 1.
Preferably, the cationic polymer is selected from aminoalkyl methacrylate copolymer, polyvinylacetal diethylaminoacetate and chitosan. As an example of the aminoalkyl methacrylate copolymer butyl methacrylate/(2-dimethylaminoethyl)- methacrylate/methyl methacrylate copolymer (1 : 2 : 1), which is marketed under the tradename Eudragit® E, may be used. Chitosan is soluble in water at a pH of 6.5 and below; Eudragit® E is soluble in water at a pH of 5 or below, while polyvinylacetal diethylaminoacetate is soluble in water at a pH of 5.8 and below.
The solid dispersion of the present invention may contain a pharmaceutical excipient selected from a filler, a disintegrant and a surfactant.
Examples of fillers include microcrystalline cellulose, calcium hydrogen phosphate (anhydrous or dihydrate), lactose (anhydrous or monohydrate), calcium carbonate, magnesium carbonate, silicified microcrystalline cellulose, powder cellulose and mannitol. Preferably, the filler is selected from microcrystalline cellulose, powder cellulose, silicified microcrystalline cellulose and calcium hydrogen phosphate, whereby microcrystalline cellulose is most preferably used.
Examples of disintegrants include sodium starch glycolate, croscarmellose sodium and crospovidone, whereby the most preferred disintegrant is crospovidone.
Examples of surfactants include polyoxyethylene stearate, sodium lauryl sulphate, sorbitan fatty acid esters (e.g. sorbitan monolaurate or sorbitan monopalmitate), polyoxyethylene sorbitan fatty acid esters (e.g. Polysorbate 80) and polyoxyethylene castor oil. However, it is preferred that the solid dispersion of the present invention does not contain a surfactant.
In a preferred embodiment of the present invention, the solid dispersion consists of ritonavir, the cationic polymer, a filler and a disintegrant. Preferably, the cationic polymer is an aminoalkyl methacrylate copolymer, e.g. butyl methacrylate/(2-di- methylaminoethyl)methacrylate/methyl methacrylate copolymer (1 : 2 : 1), the filler is microcrystalline cellulose, and the disintegrant is crospovidone.
The present invention also relates to a pharmaceutical composition for oral administration containing the solid dispersion of the present invention. The pharmaceutical composition may contain, besides the pharmaceutical excipients optionally contained in the solid dispersion, a filler, disintegrant and surfactant, which may be identical to those contained in the solid dispersion. The pharmaceutical composition may, additionally, contain a binder, a glidant and/or a lubricant.
Examples of binders include hydroxypropyl methylcellulose (HPMC), methylcellu- lose, hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (povidone), polyvinyl alcohol, a vinylpyrrolidone/vinyl acetate copolymer (e.g. copovidone) and pregelati nized starch.
Examples of glidants include silicon dioxide (silica) and magnesium silicate.
Examples of lubricants include magnesium stearate, calcium stearate, zinc stearate, talc, sodium stearyl fumarate and glyceryl dibehenate.
The pharmaceutical composition of the present invention may be a tablet (including multiparticulate drug delivery systems) or a capsule that contains the solid dispersion of the present invention as particles (powder, granules or pellets), optionally in admixture with pharmaceutical excipients, and/or as minitablets.
The pharmaceutical composition of the present invention is preferably a tablet optionally coated with a film-coating. Commercially available film-coating systems containing polyvinyl alcohol as coating polymer, which are marketed under the tradename Opadry®, may be used.
The pharmaceutical composition may further contain a HIV protease inhibitor. If present, the HIV protease inhibitor is preferably not contained in the ritonavir- containing solid dispersion. The HIV protease inhibitor may be selected from darunavir, lopinavir, atazanavir, tipranavir and saquinavir. In a preferred embodiment, the pharmaceutical composition is an optionally film-coated multi-layer tablet containing ritonavir in a first layer and the HIV protease inhibitor in a second layer. For example, the multi-layer tablet may be an optionally film-coated bilayer tablet containing ritonavir in the first layer and darunavir in the second layer.
The pharmaceutical composition of the present invention is suitable, optionally in combination with other antiretroviral agents, for the treatment of HIV infection, e.g. HIV-l infection. The solid dispersion of the present invention may be prepared by melt-extrusion, spray-drying or spray-granulation, whereby spray-granulation is the preferred method. Hence, the solid dispersion of the present invention may be prepared by i) dissolving ritonavir and the cationic polymer containing an amino group in a granulation liquid, and
ii) spraying the solution obtained in step (i) onto a pharmaceutical excipient to obtain the solid dispersion in form of granules.
Usually, the granulation liquid is an organic solvent, preferably an alcohol, such as ethanol. In a preferred embodiment of the present invention, the pharmaceutical excipient used in method step (ii) is selected from a filler and a disintegrant.
The pharmaceutical composition for oral administration according to the present invention may be prepared by iii) mixing the solid dispersion of the present invention, which is preferably obtained by steps (i) and (ii) mentioned above, and a pharmaceutical excipient, and
iv) subjecting the mixture obtained in step (iii) to compression.
In a preferred embodiment of the present invention, the pharmaceutical composition contains a filler and disintegrant in the solid dispersion, i.e. as intragranular compo nents, and a disintegrant, lubricant and glidant as extragranular components.
If a HIV protease inhibitor is additionally contained in the pharmaceutical compo sition, the HIV protease inhibitor is preferably not contained in the ritonavir- containing solid dispersion. This can be achieved by iii) mixing the solid dispersion of the present invention, which is preferably obtained by steps (i) and (ii) mentioned above, a pharmaceutical excipient and the HIV protease inhibitor, and
iv) subjecting the mixture obtained in step (iii) to compression.
In this embodiment, the HIV protease inhibitor is contained in the pharmaceutical composition as extragranular component. Alternatively, the ritonavir-containing solid dispersion is contained in a first layer and the HIV protease inhibitor is contained in a second layer of an optionally film-coated multi-layer tablet. Preferably, the HIV protease inhibitor is darunavir.
The present invention also relates to a bilayer tablet containing ritonavir in a first layer and darunavir in a second layer. The optionally film-coated bilayer tablet may be prepared by i) dissolving ritonavir and the cationic polymer containing an amino group in a granulation liquid,
ii) spraying the solution obtained in step (i) onto a pharmaceutical excipient to obtain a solid dispersion in the form of granules, and
iii) mixing the solid dispersion obtained in step (ii) and a pharmaceutical excipient, v) subjecting a mixture containing darunavir and a pharmaceutical excipient to dry-granulation,
vi) mixing the granules obtained in step (v) and a pharmaceutical excipient, vii) layering the mixture obtained in step (iii) onto the mixture obtained in step (vi),
viii) subjecting the two layers obtained in step (vii) to compression, and ix) optionally subjecting the bilayer tablet obtained in step (viii) to film-coating.
Typically, the pharmaceutical excipient used in step (ii) is a filler and a disintegrant; the pharmaceutical excipient used in steps (iii) and (vi) is a disintegrant, a glidant and a lubricant; the pharmaceutical excipient used in step (v) is a filler and a lubricant.
The following examples are intended to further illustrate the present invention.
Examples
Manufacturing process
A. Darunavir layer
A-l: Sift all dry mix materials through appropriate sieve
A-2: Mix the sifted materials for appropriate time
A-3: Lubricate the mix with magnesium stearate
A-4: Compact the lubricated blend using roller compactor
A-5: Size the compacted flakes through appropriate sieve
A-6: Blend sifted granules for appropriate time
A-7: To the final sifted and blended granules of appropriate particle size distribution add crospovidone and colloidal silicon dioxide and mix for appropriate time
A-8: Lubricate the mixed product of previous step with magnesium stearate
B. Ritonavir layer
B-l: Dissolve Eudragit® in ethanol
B-2: In the solution dissolve ritonavir and stir for appropriate time
B-3: Load microcrystalline cellulose in the fluid bed processor, along with crospovidone
B-4: Spray granulate with the solution of step B-2 to obtain a solid solution of ritonavir within a Eudragit® matrix
B-5: Mix the resulting granules with crospovidone and colloidal silicon dioxide for appropriate time
B-6: Lubricate with sodium stearyl fumarate
C. Compression
Compress the two layers in a bilayer tablet
I). Film-coating
Optionally, film-coat the bilayer tablet

Claims

Claims
1. A solid dispersion comprising ritonavir, a cationic polymer containing an amino group, and optionally a pharmaceutical excipient.
2. The solid dispersion according to claim 1, wherein the weight ratio of the cationic polymer to ritonavir is 6 : 1 to 1 : 2, preferably 3 : 1 to 2 : 3, more preferred 3 : 2 to 1 : 1.
3. The solid dispersion according to claim 1 or 2, wherein the cationic polymer is selected from aminoalkyl methacrylate copolymer, polyvinylacetal diethylaminoacetate and chitosan.
4. The solid dispersion according to any one of the preceding claims, wherein the pharmaceutical excipient is selected from a filler, a disintegrant and a surfactant.
5. The solid dispersion according to claim 4, wherein the filler is selected from microcrystalline cellulose, powder cellulose, silicified microcrystalline cellulose and calcium hydrogen phosphate.
6. The solid dispersion according to claim 4, wherein the disintegrant is selected from sodium starch glycolate, croscarmellose sodium and crospovidone.
7. The solid dispersion according to claim 4, wherein the surfactant is selected from sorbitan monolaurate, sorbitan monopalmitate and polyoxyethylene castor oil.
8. The solid dispersion according to any one of the preceding claims, wherein the solid dispersion consists of ritonavir, a cationic polymer, a filler and a disintegrant.
9. The solid dispersion according to claim 8, wherein the cationic polymer is an aminoalkyl methacrylate copolymer, preferably butyl methacrylate/(2-di- methylaminoethyl)methacrylate/methyl methacrylate copolymer (1 : 2 : 1), wherein the filler is microcrystalline cellulose, and wherein the disintegrant is crospovidone.
10. A pharmaceutical composition for oral administration containing the solid dispersion as defined in any one of claims 1-9.
11. The pharmaceutical composition according to claim 10, wherein the composition further contains a HIV protease inhibitor.
12. The pharmaceutical composition according to claim 11, wherein the HIV protease inhibitor is not contained in the ritonavir-containing solid dispersion.
13. The pharmaceutical composition according to claim 11 or 12, wherein the HIV protease inhibitor is selected from darunavir, lopinavir, atazanavir, tipranavir and saquinavir.
14. The pharmaceutical composition according to any one of claims 11-13, wherein the composition is an optionally film-coated multi-layer tablet containing ritonavir in a first layer and the HIV protease inhibitor in a second layer.
EP19725121.8A 2018-05-18 2019-05-16 Solid dispersion containing ritonavir Withdrawn EP3793530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18173268.6A EP3569225A1 (en) 2018-05-18 2018-05-18 Solid dispersion containing ritonavir
PCT/EP2019/062639 WO2019219823A1 (en) 2018-05-18 2019-05-16 Solid dispersion containing ritonavir

Publications (1)

Publication Number Publication Date
EP3793530A1 true EP3793530A1 (en) 2021-03-24

Family

ID=62217853

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18173268.6A Withdrawn EP3569225A1 (en) 2018-05-18 2018-05-18 Solid dispersion containing ritonavir
EP19725121.8A Withdrawn EP3793530A1 (en) 2018-05-18 2019-05-16 Solid dispersion containing ritonavir

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18173268.6A Withdrawn EP3569225A1 (en) 2018-05-18 2018-05-18 Solid dispersion containing ritonavir

Country Status (2)

Country Link
EP (2) EP3569225A1 (en)
WO (1) WO2019219823A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2759547C1 (en) * 2020-12-04 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Method for application of copolymer of dimethylaminoethylmethacrylate, butylmethacrylate and methyl methacrylate to increase solubility and/or bioavailability of antiretroviral active pharmaceutical substance in manufacture of solid dispersion on granular carrier
CN113318076B (en) * 2021-06-02 2022-09-23 聊城大学 A kind of ritonavir solid dispersion with both solubilization and crystallization inhibition effects and preparation method thereof
CN114668737A (en) * 2022-03-02 2022-06-28 乐普制药科技有限公司 Compound bilayer tablet containing ritonavir pellets for treating novel coronavirus
CN114557967B (en) * 2022-03-17 2023-06-02 乐普制药科技有限公司 Preparation method of ritonavir solid dispersion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189402A1 (en) * 2012-03-28 2017-07-06 Abbvie Inc. Solid dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121765A (en) 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
ES2235991T3 (en) 1999-11-12 2005-07-16 Abbott Laboratories PHARMACEUTICAL FORMULATIONS OF SOLID DISPERSION.
DE10239999A1 (en) * 2002-08-27 2004-03-04 Röhm GmbH & Co. KG Granules or powders for the preparation of coating and binding agents for dosage forms
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
GT200800303A (en) 2007-12-24 2009-09-18 ANTI-RETROVIRAL COMBINATION
EP2391350A1 (en) * 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
WO2011141192A1 (en) * 2010-05-10 2011-11-17 Evonik Röhm Gmbh Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
EP2564832A1 (en) * 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
EP2958563A2 (en) * 2013-02-20 2015-12-30 AbbVie Inc. Tablet dosage form comprising ritonavir and lopinavir

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189402A1 (en) * 2012-03-28 2017-07-06 Abbvie Inc. Solid dosage forms

Also Published As

Publication number Publication date
WO2019219823A1 (en) 2019-11-21
EP3569225A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
JP2008531509A (en) Tablets with improved dispersibility of pharmaceutical ingredients
EP3793530A1 (en) Solid dispersion containing ritonavir
KR101237646B1 (en) Solid dispersion comprising celecoxib with improved bioavailibity, pharmaceutical composition comprising the solid dispersion, and preparation method of the solid dispersion
AU2014345629B2 (en) Mesoporous dosage forms for poorly soluble drugs
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
US20180344646A1 (en) Amorphous dispersion granules and oral dosage forms
JP2015522653A (en) Pharmaceutical composition of proton pump inhibitor
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2016142821A2 (en) Compositions containing a thrombin inhibitor
WO2011080706A1 (en) Enhanced solubility of ziprasidone
EP2701689A2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
CN106727382A (en) A kind of Carvedilol supersaturated self-emulsion dispersible tablet and preparation method thereof
WO2011161689A1 (en) Imatinib mesilate pharmaceutical tablet
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2020122244A1 (en) Tablet and method for producing same
EP3761965A1 (en) Ticagrelor-containing tablet formulation
AU2018454263B2 (en) Dosage form containing abiraterone acetate
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
WO2024218790A1 (en) A pharmaceutical composition of ubrogepant and their process for the preparation of solid dosage form for treating migraine
WO2008068727A2 (en) Pharmaceutical composition comprising candesartan cilexetil
ES2673870T3 (en) Solid oral dosage formulation of [(1S) -1 - {[(2S, 4R) -4- (7-chloro-4-methoxyisoquinolin-1-yloxy) -2 - ({(1R, 2S) -1- [ 1,1-dimethylethyl (cyclopropylsulfonyl) carbamoyl] -2-ethenylcyclopropyl} carbamoyl) pyrrolidin-1-yl] carbonyl} -2,2-dimethyl-propyl] carbamate
JP2004238348A (en) Itraconazole preparation for oral administration
US20130190337A1 (en) Solid dosage forms of hiv protease inhibitors
US20060141044A1 (en) Pharmaceutical compositions based on diclofenac derivate
JP2005213220A (en) Controlled-release medicinal composition and preparation using the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230722